Cochrane · systematic review · CD000206

Calcium channel blockers for antipsychotic‐induced tardive dyskinesia

Essali, A, Soares‐Weiser, K, Bergman, H, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library

Schizophrenia2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Calcium channel blocking drugs for people with antipsychotic‐induced tardive dyskinesia

Population: people with antipsychotic‐induced tardive dyskinesia
7 questions
OutcomeEffectEvidenceStatus / GRADE
Tardive dyskinesia ‐ not improved to a clinically important extent
no estimate extracted2 studies · 37 participantsVery low
Downgraded: risk of bias, imprecision
Tardive dyskinesia ‐ deterioration
no estimate extractedNRNo studies
Adverse effects ‐ any important adverse effects
no estimate extracted1 study · 20 participantsVery low
Downgraded: risk of bias, imprecision, indirectness
Adverse effects ‐ important extrapyramidal adverse effects
no estimate extractedNRNo studies
Mental state ‐ deterioration
no estimate extracted1 study · 18 participantsVery low
Downgraded: risk of bias, imprecision, indirectness
Acceptability of treatment ‐ leaving the study early
no estimate extractedNRNo studies
Social confidence, social inclusion, social networks or personalised quality of life measures ‐ no clinically significant change
no estimate extractedNRNo studies